Limits...
Effect of evodiamine and berberine on miR-429 as an oncogene in human colorectal cancer.

Liu H, Huang C, Wu L, Wen B - Onco Targets Ther (2016)

Bottom Line: Our results suggested that E-cadherin and Par3 were remarkably decreased in tumor tissues compared with those in normal tissues, and miR-429 was upregulated in tumor tissues.After treatment of BER and EVO, the level of miR-429 was lower in tumor tissues than in normal tissues.The data suggested that BER and EVO can be potential therapeutic agents for CRC, as they downregulated the expression level of miR-429.

View Article: PubMed Central - PubMed

Affiliation: Institute of Spleen and Stomach, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China.

ABSTRACT
Loss of epithelial organization and deregulated microRNAs are hallmarks of malignant carcinomas, but the relationship between them has been poorly understood. This study was designed to investigate the changes in the expression of E-cadherin, Par3, and miR-429 during the development of human colorectal cancer (CRC). E-cadherin and Par3 levels were quantitatively detected by immunohistochemistry and Western blotting. An in vitro culture of colorectal tissue was established to analyze the effect of berberine (BER) and evodiamine (EVO) on the level of miR-429. Our results suggested that E-cadherin and Par3 were remarkably decreased in tumor tissues compared with those in normal tissues, and miR-429 was upregulated in tumor tissues. After treatment of BER and EVO, the level of miR-429 was lower in tumor tissues than in normal tissues. This study investigated the potential relationship between miR-429, E-cadherin, and Par3 in CRC. The data suggested that BER and EVO can be potential therapeutic agents for CRC, as they downregulated the expression level of miR-429.

No MeSH data available.


Related in: MedlinePlus

qRT-PCR of miR-429 treated with different dosages of BER and EVO.Notes: (A) Expression of miR-429 after 72 hours of treatment with BER. (B) Expression of miR-429 after 72 hours of treatment with EVO. *Denotes statistical significance compared with control group; **represents statistical significance compared with tumor tissue.Abbreviations: BER, berberine; EVO, evodiamine; qRT-PCR, quantitative reverse transcription polymerase chain reaction.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4940014&req=5

f3-ott-9-4121: qRT-PCR of miR-429 treated with different dosages of BER and EVO.Notes: (A) Expression of miR-429 after 72 hours of treatment with BER. (B) Expression of miR-429 after 72 hours of treatment with EVO. *Denotes statistical significance compared with control group; **represents statistical significance compared with tumor tissue.Abbreviations: BER, berberine; EVO, evodiamine; qRT-PCR, quantitative reverse transcription polymerase chain reaction.

Mentions: Immunohistochemical staining suggested that E-cadherin and Par-3 were expressed in all tissue specimens, and were dominantly observed in the cytoplasm and membrane (Figure 2B and C). The tissues were cultured for 3 and 25 days and subsequently stained with Calcein-AM/PI (Figure 2D). Western blotting showed that the expression levels of E-cadherin and Par-3 in the tumor tissues were significantly lower than those in the normal tissues (Figure 2E and F). MicroRNAs in the tissues treated with BER and EVO were also detected by qRT-PCR. The expression levels of miR-429 were significantly upregulated in all the treatment groups compared with those in the control group. However, the level of miR-429 in tumor tissues was considerably lower than that in normal tissues treated with BER and EVO, suggesting that the expression level of miR-429 was regulated by BER and EVO treatment, as illustrated in Figure 3.


Effect of evodiamine and berberine on miR-429 as an oncogene in human colorectal cancer.

Liu H, Huang C, Wu L, Wen B - Onco Targets Ther (2016)

qRT-PCR of miR-429 treated with different dosages of BER and EVO.Notes: (A) Expression of miR-429 after 72 hours of treatment with BER. (B) Expression of miR-429 after 72 hours of treatment with EVO. *Denotes statistical significance compared with control group; **represents statistical significance compared with tumor tissue.Abbreviations: BER, berberine; EVO, evodiamine; qRT-PCR, quantitative reverse transcription polymerase chain reaction.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4940014&req=5

f3-ott-9-4121: qRT-PCR of miR-429 treated with different dosages of BER and EVO.Notes: (A) Expression of miR-429 after 72 hours of treatment with BER. (B) Expression of miR-429 after 72 hours of treatment with EVO. *Denotes statistical significance compared with control group; **represents statistical significance compared with tumor tissue.Abbreviations: BER, berberine; EVO, evodiamine; qRT-PCR, quantitative reverse transcription polymerase chain reaction.
Mentions: Immunohistochemical staining suggested that E-cadherin and Par-3 were expressed in all tissue specimens, and were dominantly observed in the cytoplasm and membrane (Figure 2B and C). The tissues were cultured for 3 and 25 days and subsequently stained with Calcein-AM/PI (Figure 2D). Western blotting showed that the expression levels of E-cadherin and Par-3 in the tumor tissues were significantly lower than those in the normal tissues (Figure 2E and F). MicroRNAs in the tissues treated with BER and EVO were also detected by qRT-PCR. The expression levels of miR-429 were significantly upregulated in all the treatment groups compared with those in the control group. However, the level of miR-429 in tumor tissues was considerably lower than that in normal tissues treated with BER and EVO, suggesting that the expression level of miR-429 was regulated by BER and EVO treatment, as illustrated in Figure 3.

Bottom Line: Our results suggested that E-cadherin and Par3 were remarkably decreased in tumor tissues compared with those in normal tissues, and miR-429 was upregulated in tumor tissues.After treatment of BER and EVO, the level of miR-429 was lower in tumor tissues than in normal tissues.The data suggested that BER and EVO can be potential therapeutic agents for CRC, as they downregulated the expression level of miR-429.

View Article: PubMed Central - PubMed

Affiliation: Institute of Spleen and Stomach, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China.

ABSTRACT
Loss of epithelial organization and deregulated microRNAs are hallmarks of malignant carcinomas, but the relationship between them has been poorly understood. This study was designed to investigate the changes in the expression of E-cadherin, Par3, and miR-429 during the development of human colorectal cancer (CRC). E-cadherin and Par3 levels were quantitatively detected by immunohistochemistry and Western blotting. An in vitro culture of colorectal tissue was established to analyze the effect of berberine (BER) and evodiamine (EVO) on the level of miR-429. Our results suggested that E-cadherin and Par3 were remarkably decreased in tumor tissues compared with those in normal tissues, and miR-429 was upregulated in tumor tissues. After treatment of BER and EVO, the level of miR-429 was lower in tumor tissues than in normal tissues. This study investigated the potential relationship between miR-429, E-cadherin, and Par3 in CRC. The data suggested that BER and EVO can be potential therapeutic agents for CRC, as they downregulated the expression level of miR-429.

No MeSH data available.


Related in: MedlinePlus